Financial Performance - The company's revenue for Q1 2022 was ¥53,106,464.55, a decrease of 14.66% compared to ¥62,227,442.74 in the same period last year[3] - Net profit attributable to shareholders was ¥7,906,004.78, down 25.22% from ¥10,572,246.52 year-on-year[3] - Basic and diluted earnings per share were both ¥0.1174, reflecting a decrease of 32.72% from ¥0.1745 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 53,106,464.55, a decrease of 14.5% compared to CNY 62,227,442.74 in the same period last year[22] - Net profit for Q1 2022 was CNY 7,906,004.78, representing a decline of 25.3% from CNY 10,572,246.52 in Q1 2021[24] - Earnings per share for Q1 2022 was CNY 0.1174, down from CNY 0.1745 in the previous year[25] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥15,610,919.58, a 683.96% improvement from -¥2,673,267.98 in the previous year[3] - The company's cash and cash equivalents amounted to RMB 637,637,486.24, up from RMB 148,630,019.72 at the beginning of the year, reflecting a substantial growth in liquidity[19] - The net cash flow from operating activities was 15,610,919.58 CNY, a significant improvement compared to -2,673,267.98 CNY in the previous year[28] - The net cash flow from investing activities was 64,048,790.21 CNY, recovering from a negative cash flow of -1,884,270.00 CNY in the same period last year[28] - The net cash flow from financing activities amounted to 409,347,756.73 CNY, indicating strong capital inflow[29] - The total cash and cash equivalents at the end of the period reached 637,080,557.42 CNY, up from 102,623,538.74 CNY year-over-year[29] - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency[28] Assets and Equity - Total assets at the end of the reporting period reached ¥1,002,392,131.32, representing a 68.58% increase from ¥594,606,181.26 at the end of the previous year[3] - Shareholders' equity attributable to the company was ¥922,977,118.32, up 76.09% from ¥524,138,056.37 at the end of the last year[3] - The total current assets increased to RMB 725,917,369.13 from RMB 314,929,356.70, showcasing a strong improvement in the company's short-term financial position[20] - The total non-current assets decreased slightly to RMB 276,474,762.19 from RMB 279,676,824.56, suggesting stability in long-term investments[20] - Total equity attributable to shareholders increased to CNY 922,977,118.32 from CNY 524,138,056.37, a significant rise of 76.1%[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,577[10] - The company has issued a total of 20,200,986 shares in its initial public offering, which was approved by the China Securities Regulatory Commission[17] Operational Highlights - The company plans to continue its market expansion and product development strategies, aiming for sustainable growth in the upcoming quarters[17] - The company is focusing on research and development of new products and technologies to enhance its competitive edge in the pharmaceutical industry[17] Donations and Subsidies - The company received government subsidies amounting to ¥770,553.18, which are closely related to its normal business operations[6] - The company made a donation of ¥1,000,000 to the Red Cross Society of Panshi City for epidemic prevention support[6] Other Financial Metrics - Total operating costs for Q1 2022 were CNY 44,475,693.43, down 14.4% from CNY 51,939,691.57 year-on-year[22] - Accounts payable increased to CNY 8,386,126.64 from CNY 6,235,531.98, reflecting a rise of 34.5%[21] - Other payables rose to CNY 27,186,912.80 from CNY 18,852,139.04, marking an increase of 43.8%[21] - Total liabilities amounted to CNY 79,415,013.00, up from CNY 70,468,124.89, indicating a growth of 12.8%[21] - Deferred income decreased slightly to CNY 35,008,213.57 from CNY 35,778,766.75, a decline of 2.1%[21] - The report for the first quarter was not audited, which may affect the reliability of the financial data presented[30]
西点药业(301130) - 2022 Q1 - 季度财报